Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 4, Issue 1, Pages 18
Publisher
Springer Nature
Online
2011-04-27
DOI
10.1186/1756-8722-4-18
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Docetaxel-based combination therapy for castration-resistant prostate cancer
- (2010) M. D. Galsky et al. ANNALS OF ONCOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Castration-Resistant Prostate Cancer
- (2010) Giuseppe Di Lorenzo et al. DRUGS
- Zibotentan for the treatment of castrate-resistant prostate cancer
- (2010) Dale R Shepard et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer
- (2010) Neeraj Agarwal et al. Future Oncology
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Yang-Min Ning et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Cabazitaxel
- (2010) Matthew D. Galsky et al. NATURE REVIEWS DRUG DISCOVERY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
- (2009) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
- (2009) L. Zhao et al. CANCER RESEARCH
- Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
- (2009) M.-E. Taplin et al. CLINICAL CANCER RESEARCH
- Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
- (2009) Kim N. Chi et al. EUROPEAN UROLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications
- (2008) Elahe A. Mostaghel et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Targeting the androgen receptor pathway in prostate cancer
- (2008) Yu Chen et al. CURRENT OPINION IN PHARMACOLOGY
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
- (2008) Nicholas D. James et al. EUROPEAN UROLOGY
- ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer
- (2008) Ruth Warren et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer
- (2007) Tomasz M. Beer et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search